Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Executive Summary

• Theralase Technologies Inc. has filed and obtained a receipt for a final base shelf prospectus with Canadian securities regulatory authorities.
• The prospectus provides the company with the ability to offer up to C$100 Million in various securities, including common shares, warrants, subscription receipts, and debt securities.
• The offering period for these securities is set for 25 months, though the company currently has no intention to issue securities under this prospectus.

Key Details

• Filing Type: Final base shelf prospectus dated June 29, 2026.
• Jurisdiction: All provinces and territories of Canada.
• Maximum Offering Amount: Up to C$100 Million.
• Securities Types: Common shares, warrants, subscription receipts, debt securities, or any combination thereof.
• Offering Period: 25 months.
• Current Intent: The Company has no present intention to offer the Securities pursuant to the Prospectus.
• Future Offerings: Any future offering will be made by way of a Prospectus supplement containing specific terms, which will be filed with applicable securities regulatory authorities.
• Use of Proceeds (Potential): To fund the commercial development of various cancer, virus, and bacteria platforms, support the pivotal non-muscle invasive bladder cancer clinical program, advance the oncological pipeline, and continue pharmaceutical platform development.

Notable Quotes

• "The approval of the Prospectus represents an important milestone for the Company, providing up to C$100 Million of capital, if and when required, to fund the commercial development of various cancer, virus and bacteria platforms. Access to capital markets, as opportunities arise, supports our corporate strategy of simultaneously advancing numerous, value-driven strategic initiatives... The Company believes that maintaining access to flexible financing will support its ongoing efforts to create long-term shareholder value, through successful achievement of key clinical, regulatory and commercial milestones." — Roger DuMoulin-White, President and Chief Executive Officer